Treatment Recommendation
For this 71-year-old woman with favorable lipid parameters (LDL-C 134 mg/dL, HDL-C 96 mg/dL, non-HDL-C 148 mg/dL, triglycerides 68 mg/dL), the decision to initiate statin therapy depends entirely on her cardiovascular risk status—specifically whether she has established atherosclerotic cardiovascular disease (ASCVD) or what her 10-year ASCVD risk is if she has no prior cardiovascular events.
Risk Stratification is Critical
The 2018 ACC/AHA Cholesterol Guidelines 1 frame all lipid-lowering decisions around four major statin benefit groups, with age and cardiovascular risk as the primary determinants. For a 71-year-old woman, the approach differs dramatically based on:
If She Has Clinical ASCVD (Secondary Prevention)
- Initiate moderate-intensity statin therapy immediately 1
- The guidelines explicitly state that moderate-intensity statins reduce major vascular events and coronary deaths in patients with ASCVD, with no upper age cutoff identified for this benefit 1
- Target: Reduce LDL-C by 30-49% (from 134 mg/dL to approximately 68-94 mg/dL)
- Examples: Atorvastatin 10-20 mg daily or rosuvastatin 5-10 mg daily
If she is very high-risk ASCVD (multiple major events or one major event plus multiple high-risk conditions), consider high-intensity statin therapy to achieve ≥50% LDL-C reduction, targeting LDL-C <70 mg/dL 1
If She Has NO Clinical ASCVD (Primary Prevention)
The decision becomes more nuanced and requires calculating her 10-year ASCVD risk:
- If 10-year ASCVD risk ≥7.5%: Moderate-intensity statin is reasonable after risk discussion 1
- If 10-year ASCVD risk 5-7.4%: Consider risk-enhancing factors (family history, metabolic syndrome, chronic kidney disease, inflammatory conditions, premature menopause, etc.) to guide decision 1
- If 10-year ASCVD risk <5%: Generally do not initiate statin therapy
Important Clinical Context for This Patient
Her lipid profile is actually quite favorable for a 71-year-old:
- HDL-C of 96 mg/dL is exceptionally high and protective
- Triglycerides of 68 mg/dL are optimal
- Non-HDL-C of 148 mg/dL is only mildly elevated
- LDL-C of 134 mg/dL is borderline elevated but not dramatically high
Recent expert consensus 2 emphasizes that in adults >75 years without ASCVD, shared decision-making is paramount. The decision must weigh:
- Estimated life expectancy
- Functional status and frailty
- Cognitive function
- Co-morbidities
- Patient preferences and goals of care
Practical Algorithm
Step 1: Determine if she has clinical ASCVD (prior MI, ACS, stroke, TIA, peripheral arterial disease, coronary revascularization)
- YES → Start moderate-intensity statin (no age limit for benefit) 1
- NO → Proceed to Step 2
Step 2: Calculate 10-year ASCVD risk using pooled cohort equations
- ≥7.5% → Discuss moderate-intensity statin; benefits likely outweigh risks 1
- 5-7.4% → Assess risk-enhancing factors; consider statin if present
- <5% → Lifestyle modification; generally defer statin
Step 3: Engage in shared decision-making discussing:
- Absolute risk reduction potential
- Statin-associated muscle symptoms (most common concern)
- Very low risk of incident diabetes
- No credible evidence of cognitive harm (preponderance shows neutral or protective effects) 2
- Patient's health goals and life expectancy
Common Pitfalls to Avoid
- Do not automatically treat based on LDL-C alone in primary prevention at age 71—risk stratification is mandatory 1
- Do not withhold statins solely due to age if she has ASCVD—the benefit persists in older adults 1
- Do not ignore her excellent HDL-C—this is highly protective and modifies overall risk
- Do not use outdated cholesterol/HDL ratios—these are obsolete measures 3
- Do not order fasting lipids—non-fasting samples are appropriate for screening and treatment decisions 4, 3
If Statin Therapy is Initiated
Monitor for:
- LDL-C reduction of 30-49% on moderate-intensity or ≥50% on high-intensity therapy 1
- Muscle symptoms (most common side effect)
- Baseline and follow-up hepatic transaminases and CK only if symptomatic 1
The evidence strongly supports that benefits outweigh risks in appropriately selected older adults 5, 6, 2, but the key is appropriate patient selection based on cardiovascular risk, not lipid levels alone.